Theriva Biologics (TOVX) Shares Outstanding (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Shares Outstanding (Entity) of $45.9 million for Q1 2026, up 1533.48% year-over-year from $2.8 million in Q1 2025, and up 278.24% quarter-over-quarter from $12.1 million in Q4 2025.
Theriva Biologics (TOVX) Shares Outstanding (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Shares Outstanding (Entity) for 17 consecutive years, with $45.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 1533.48% year-over-year to $45.9 million; the TTM figure through Mar 2026 stood at $45.9 million (up 1533.48% YoY), while the FY2025 annual figure was $12.1 million, up 800.56% from the prior year.
- Shares Outstanding (Entity) rose to $45.9 million in Q1 2026 per TOVX's latest filing, from $12.1 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $45.9 million in Q1 2026 and bottomed at $633751.0 in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $5.1 million across 5 years, with a median of $714731.0 in 2023.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) increased 0.0% — and 2026, when it soared 1533.48%.
- Theriva Biologics' Shares Outstanding (Entity) stood at $633762.0 in 2022, then gained by 12.78% to $714731.0 in 2023, then soared by 88.62% to $1.3 million in 2024, then jumped by 800.56% to $12.1 million in 2025, then surged by 278.24% to $45.9 million in 2026.
- Business Quant data shows TOVX's Shares Outstanding (Entity) at $45.9 million in Q1 2026, $12.1 million in Q4 2025, and $10.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | 45.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.89 Mn |
| Mar 31, 2026 | 41.07 Mn |
| Dec 31, 2025 | 12.14 Mn |
| Sep 30, 2025 | 9.68 Mn |
| Jun 30, 2025 | 6.75 Mn |
| Mar 31, 2025 | 2.78 Mn |
| Dec 31, 2024 | 1.35 Mn |
| Sep 30, 2024 | 1.13 Mn |
| Jun 30, 2024 | 775,736.00 |
| Mar 31, 2024 | 685,922.00 |
| Dec 31, 2023 | 644,281.00 |
| Sep 30, 2023 | 681,708.00 |
| Jun 30, 2023 | 606,648.00 |
| Mar 31, 2023 | 604,962.00 |
| Dec 31, 2022 | 613,093.00 |
| Sep 30, 2022 | 633,762.00 |
| Jun 30, 2022 | 633,762.00 |
| Mar 31, 2022 | 552,806.00 |
| Dec 31, 2021 | 487,500.00 |
| Sep 30, 2021 | 528,170.00 |